Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722852 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee
A Phase 3 study, sponsored by IDEA.
- Completed
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
NCT00722852: Completed Phase 3 study, sponsored by IDEA.
NCT00722852 is a Phase 3 study that has completed, run by IDEA. The registered enrollment target is 555 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722852, a Phase 3 study, has completed, sponsored by IDEA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
Study Summary
The purpose of this study is to provide replicated evidence of safety and efficacy of 100 mg ketoprofen in Diractin®.
Interventions
- DRUG Placebo
- DRUG ketoprofen in Diractin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00722852 record still lists
NCT00722852 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00722852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00722852 about?
NCT00722852 is a clinical study titled "Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee". The purpose of this study is to provide replicated evidence of safety and efficacy of 100 mg ketoprofen in Diractin®.
What is the current status of trial NCT00722852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2008-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00722852?
The interventions under investigation include: Placebo (DRUG), ketoprofen in Diractin® (DRUG).
Who is sponsoring clinical trial NCT00722852?
This trial is sponsored by IDEA, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00722852's enrollment target sits among peer trials
555 676th of 2000 higher than 1,323 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia